ALLO News and Press, Allogene Therapeutics Inc. From 02/28/24

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will partic...

First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...

No Impact on Cash, Cash Equivalents and Marketable Investments, Cash Runway or Business Operations Company Targeting On or Before March 14, 2024 to File Amended Financial Statements and Report Fourth Quarter and Full Year 2023 Financial Results SOUTH SAN FRANCISCO, Calif., Feb. 16, 20...

2024-02-02 15:00:00 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...

2024-01-22 18:34:33 ET Summary Cellectis is a biotech company focused on developing allogeneic CAR T-cell therapy, which uses donor T cells instead of the patient's own cells. They have three main projects in clinical studies, with their most advanced therapy being outlicensed to ...

SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate...

2024-01-08 00:00:11 ET Summary Allogene Therapeutics is developing allogeneic CAR T-cell therapies for cancer management, offering advantages over autologous therapies. ALLO-501A, a CD19-directed CAR T-cell therapy, is in phase 2 trials for B-cell lymphomas and has shown promising...

2024-01-05 12:25:58 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotechnology company Allogene (NASDAQ: ALLO ) is certainly not having the day that many in the company’s C-Suite may have anticipated. Shares of ALLO stock are plunging yet ...

2024-01-05 10:00:03 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Covid-vaccine makers top laggard list, LLY and WST top gainers list Healthcare and uti...

2024-01-05 07:43:11 ET Allogene Therapeutics ( NASDAQ: ALLO ) fell ~22% premarket Friday after the cell therapy developer announced a pipeline shakeup that it said would cut costs and reduce cash burn. As part of the strategy named 2024 Platform Vision, the company will depr...